scholarly journals PECULIARITIES OF DETERMINING THE GASTRIC ACID SECRETION AND DIABETIC AUTONOMIC NEUROPATHY IN PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 2 DIABETES

2021 ◽  
Vol 74 (4) ◽  
pp. 981-985
Author(s):  
Yelyzaveta S. Sirchak ◽  
Vasilij Ye. Barani ◽  
Olena M. Odoshevska ◽  
Oksana I. Petrichko

The aim: Is to determine the peculiarities of changes in the gastric acid secretion against the background of diabetic autonomic neuropathy and autonomic dysfunction in patients with chronic pancreatitis (CP) and type 2 diabetes (T2DM). Materials and methods: We investigated 64 patients with CP and T2DM, who were included in the first group of the patients examined; Group II consisted of 40 patients with T2DM; and Group III of the patients examined consisted of 34 patients with CP. Results: Differences were found in assessing the degree of autonomic nervous system (ANS) dysfunction in the examined patients, namely – the most pronounced ANS dysfunction according to the Wayne questionnaire was diagnosed in patients Group I, while patients of Group III. Analysis of gastric acid secretion indicates that no patients of Group III had normal acidity. Normal acidity is more often found in the second group of subjects. Both in patients with CP and T2DM, and in isolation with CP, moderate hyperacidity was more often determined. Conclusions: The predominance of the parasympathetic division of the ANS, as well as manifestations of severe ANS dysfunction, are observed in patients with CP and T2DM. The prevalence of gastric hyperacidity on the background of DAN was established in patients with CP and T2DM. In this case, the absence of clinical symptoms or their minimal severity is determined, which indicates the lesion of the digestive tract in these patients.

1981 ◽  
Vol 16 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Toshio Sato ◽  
Jin-ichi Kameyama ◽  
Iwao Sasaki ◽  
Mikio Imamura ◽  
Seiki Matsuno

2020 ◽  
Author(s):  
Daniel R. Quast ◽  
Nina Schenker ◽  
Björn A. Menge ◽  
Michael A. Nauck ◽  
Christoph Kapitza ◽  
...  

<b>Objective</b> <p>Short-acting GLP-1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short- (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.</p> <p><b>Research Design and Methods</b></p> <p>57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-hour pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (<sup>13</sup>C-sodium octanoate acid breath test) and gastric acid secretion (<sup>13</sup>C-calcium carbonate breath test) were analyzed.</p> <p><b>Results</b></p> <p>Gastric emptying half-time was delayed by 52 min (16, 88) min with lixisenatide (p = 0.0065) and by 25 min (3, 46) with liraglutide (p = 0.025). There was no difference in the number of reflux episodes (33.7±4.1 vs. 40.1±5.3, p = 0.17) or the extent of gastroesophageal reflux (DeMeester-Score) (35.1±6.7 vs. 39.7±7.5, p = 0.61) with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7 (-40.6, -0.8) % (p = 0.042) with the GLP-1 RAs.</p> <p><b>Conclusions</b></p> <p>Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide, nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs.</p> <br> <br>


Sign in / Sign up

Export Citation Format

Share Document